Insider Selling: Becton Dickinson and Co (BDX) SVP Sells 2,080 Shares of Stock
Becton Dickinson and Co (NYSE:BDX) SVP Charles R. Bodner sold 2,080 shares of the firm’s stock in a transaction dated Friday, November 16th. The shares were sold at an average price of $245.83, for a total value of $511,326.40. Following the transaction, the senior vice president now owns 4,497 shares in the company, valued at $1,105,497.51. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.
Shares of Becton Dickinson and stock traded up $6.03 during trading on Friday, reaching $246.07. The company’s stock had a trading volume of 1,236,843 shares, compared to its average volume of 1,178,613. The company has a debt-to-equity ratio of 0.95, a quick ratio of 0.81 and a current ratio of 1.23. The firm has a market capitalization of $62.74 billion, a PE ratio of 22.35, a PEG ratio of 1.61 and a beta of 1.19. Becton Dickinson and Co has a one year low of $209.91 and a one year high of $265.87.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, November 6th. The medical instruments supplier reported $2.93 EPS for the quarter, hitting analysts’ consensus estimates of $2.93. The business had revenue of $4.40 billion for the quarter, compared to analyst estimates of $4.36 billion. Becton Dickinson and had a return on equity of 13.84% and a net margin of 1.47%. The firm’s revenue for the quarter was up 39.0% on a year-over-year basis. During the same period in the previous year, the company posted $2.40 earnings per share. Research analysts forecast that Becton Dickinson and Co will post 12.15 earnings per share for the current year.
Several equities analysts have weighed in on BDX shares. KeyCorp raised their target price on Becton Dickinson and from $264.00 to $273.00 and gave the company an “overweight” rating in a report on Thursday, November 8th. Wells Fargo & Co raised their target price on Becton Dickinson and from $275.00 to $290.00 and gave the company an “outperform” rating in a report on Thursday, September 6th. They noted that the move was a valuation call. Citigroup cut their target price on Becton Dickinson and from $289.00 to $279.00 and set a “buy” rating on the stock in a report on Tuesday. Barclays started coverage on Becton Dickinson and in a report on Monday, October 15th. They set an “equal weight” rating and a $278.00 target price on the stock. Finally, Morgan Stanley raised their target price on Becton Dickinson and from $250.00 to $280.00 and gave the company an “equal weight” rating in a report on Thursday, October 4th. Five analysts have rated the stock with a hold rating and ten have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $253.79.
About Becton Dickinson and
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. It operates in two segments, BD Medical and BD Life Sciences. The BD Medical segment offers syringes, pen needles, and other products for diabetes; needles, syringes, and intravenous catheters for medication delivery; prefilled IV flush syringes; regional anesthesia needles and trays; sharps disposal containers; closed-system transfer devices; skin antiseptic products; surgical and laparoscopic instrumentations; intravenous medication safety and infusion therapy delivery, and automated medication dispensing and supply management systems; medication inventory optimization and tracking systems; and prefillable drug delivery systems.
Recommended Story: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.